​

GPMed’s statement on EU Biotech Act  

GPMed welcomes the EU Biotech Act as an important step toward strengthening Europe’s position in global life sciences. The proposed framework aims to reduce regulatory barriers, accelerate innovation, and improve the translation of scientific discoveries into real-world healthcare solutions. For Austria and the wider EU, the Act represents a timely opportunity to create a more competitive, efficient, and innovation-friendly environment for clinical research and biotechnology.

​